Doppler and Biological Second Trimester Placental Insufficiency Screening (ARTULEP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00465634|
Recruitment Status : Completed
First Posted : April 25, 2007
Last Update Posted : August 9, 2013
|Condition or disease|
|Pre-Eclampsia Fetal Growth Retardation Placental Insufficiency|
Pre-eclampsia (PE) and intrauterine growth restriction (IUGR) are known as major factors in perinatal morbidity and mortality. Routine antenatal care is focused on the detection of women at increased risk to apply this population a program of careful monitoring and appropriate intervention.
Uterine artery Doppler during anomaly scan at 20 to 24 weeks in selected women at increased risk, has proved to be accurate to detect those who will develop PE or IUGR during the second half of pregnancy. Studies have reported detection rate of 50-70% for a 5% false positive rate in women developing early pre-eclampsia.
A variety of proteins and hormones have been studied as potential markers for pre-eclampsia. Among these protein serum placental leptin has demonstrated higher levels in pregnant women who will subsequently develop pre-eclampsia. However, screening performance of leptin detection in early pregnancy has never been assessed.
Our study is aimed to evaluate the performance of serum leptin measurement in association with uterine artery Doppler as a screening too for placental insufficiency.
|Study Type :||Observational|
|Actual Enrollment :||235 participants|
|Official Title:||Screening for Placental Insufficiency by a Combination of Second Trimester Uterine Artery Doppler and Maternal Serum Leptin and Lipids|
|Study Start Date :||May 2003|
|Primary Completion Date :||June 2007|
|Study Completion Date :||June 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00465634
|Olympe de Gouges Women Health Centre, Bretonneau University Hospital|
|Tours, France, 37044|
|Principal Investigator:||Franck Perrotin, MD-PhD||Tours University Hospital|